In:
Annual Review of Medicine, Annual Reviews, Vol. 60, No. 1 ( 2009-02-01), p. 139-151
Abstract:
The development of biomarkers for prostate cancer screening, detection, and prognostication has revolutionized the management of this disease. Prostate-specific antigen (PSA) is a useful, though not specific, biomarker for detecting prostate cancer. We review the literature on prostate cancer biomarkers, including serum markers (PAP, tPSA, fPSA, proPSA, PSAD, PSAV, PSADT, EPCA, and EPCA-2), tissue markers (AMACR, methylated GSTP1, and the TMPRSS2-ETS gene rearrangement), and a urine marker (DD3PCA3/UPM-3). Future research should focus on validation of already existing biomarkers and the discovery of new markers to identify men with aggressive prostate cancer.
Type of Medium:
Online Resource
ISSN:
0066-4219
,
1545-326X
DOI:
10.1146/med.2009.60.issue-1
DOI:
10.1146/annurev.med.60.042307.110714
Language:
English
Publisher:
Annual Reviews
Publication Date:
2009
detail.hit.zdb_id:
1481484-5
Permalink